TY - JOUR T1 - Faldaprevir and pegylated interferon alpha-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV JF - AIDS Y1 - 2015 A1 - D. Dieterich A1 - Nelson, M. A1 - Soriano, V. A1 - Arasteh, K. A1 - Guardiola, J.M. A1 - J K Rockstroh A1 - Bhagani, S. A1 - Laguno, M. A1 - Tural, C. A1 - Ingiliz, P. A1 - Jain, M.K. A1 - Stern, J.O. A1 - Manero, M. A1 - Vinisko, R. A1 - Kort, J. A1 - STARTVerso4 study group KW - analysis KW - Antiretroviral KW - Antiretroviral Therapy KW - co-infected KW - co-infection KW - coinfection KW - Connecticut KW - efavirenz KW - Genotype KW - genotype 1 KW - Germany KW - HCV KW - hepatitis KW - Hepatitis C KW - hepatitis C virus KW - Hiv KW - interferon KW - Liver KW - Liver Cirrhosis KW - London KW - Medicine KW - methods KW - Multivariate Analysis KW - New York KW - pegylated KW - pegylated interferon KW - protease inhibitor KW - Rna KW - Safety KW - Spain KW - sustained virologic response KW - SVR KW - Texas KW - therapy KW - treatment KW - treatment-naive VL - 29 SP - 571-581 IS - 5 ER -